Literature DB >> 32387713

Coronavirus Disease 2019 or Lung Cancer: A Differential Diagnostic Experience and Management Model From Wuhan.

Jian Zhu1, Yu Zhang1, Xu-Hui Gao1, Er-Ping Xi2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32387713      PMCID: PMC7204668          DOI: 10.1016/j.jtho.2020.04.030

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


× No keyword cloud information.
To the Editor: In the Journal of Thoracic Oncology, Tian et al. reported one patient who died of coronavirus disease-2019 (COVID-19) after undergoing lung lobectomy for adenocarcinoma. Bonomi et al. presented a patient with metastatic lung cancer who died rapidly after contracting COVID-19. Russano et al. believed that patients with tumors had a higher risk of lethal COVID-19 complications. This news seems foreboding for patients with cancer who also acquire COVID-19. Therefore, because of the dramatic COVID-19 outbreak, extreme caution is required to ensure COVID-19 is not misdiagnosed as lung cancer and to consider that COVID-19 can coexist in patients with lung cancer. However, the high-resolution computed tomography (CT) findings of some patients with COVID-19 are dominated by ground-glass opacity–like changes, and these patients can even have only one localized lesion, with vacuoles, pleural traction, and invasion of pulmonary capillaries. These observations are also highly consistent with and are classic CT findings of lung cancer. Differentiating lung cancer from COVID-19 is a challenge in Wuhan, the epicenter of the outbreak currently on controlled levels of infection, and wherein the number of patients with early-stage lung cancer and those with asymptomatic COVID-19 is increasing. , This adds to the problem of identifying those with asymptomatic COVID-19. The doctors’ concerns are twofold. First, patients with COVID-19 are being mistakenly treated for lung cancer, and these individuals could undergo an unnecessary operation. Second, patients with lung cancer with COVID-19 during the perioperative period can experience severe complications or nosocomial infection events. We took the following measures to distinguish them. First, the patients admitted to the hospital were asked about their detailed medical history, including any contact history with patients having COVID-19 and whether they had had fever, cough, diarrhea, sore throat, or other symptoms in the past 2 weeks. After stating their medical history, the patients signed a declaration form consenting to disclose their medical history without any concealment; otherwise, they would bear the legal responsibility. Second, chest CT examination, routine blood parameters, blood IgG and IgM analyses, and nucleic acid examination of pharyngeal swab specimens were performed on the patients and their companions on hospital admission. Third, only those patient companions whose tests revealed negative results were allowed to accompany the patient, and only a minimum number of people were allowed to accompany the patients. If the patients were diagnosed as having suspected COVID-19 in the above examination, they were admitted to the ward for patients with suspected COVID-19 for further investigation. If the diagnosis was confirmed, the patients were transferred to the infected area for treatment. Fourth, newly admitted patients were placed in protective isolation in single rooms. After repeated body temperature monitoring, if there were no abnormalities, and if none of the symptoms mentioned above were present after 24 hours, the patient underwent a second pharyngeal swab for nucleic acid examination. If the test result was negative, the patient was transferred to the general ward for 2 to 3 days. Patient indicator information of COVID-19 was announced in the department medical staffs’ WeChat group and was updated daily. Fifth, hospitalized patients wore masks at all times; visitors and discussions with other patients were strictly prohibited. Sixth, the department ward for suspected COVID-19 and the general ward were managed by different sets of staff, and the staff were strictly prohibited from changing wards. They also needed to follow strict protective measures among themselves, such as wearing a mask if two or more people slept in the same duty room. Seventh, patients going out for checks or eating were assigned a special route, and there was regular disinfection by professionals. Eighth, routine bronchoscopy was performed before lung surgery and nucleic acid examination was also performed along with an analysis of secretions from the lower respiratory tract. Ninth, after several days (generally 1–2 weeks) of examination and surgical preparation, patients with lung cancer and with no evidence of COVID-19 underwent a routine operation.
  4 in total

1.  Coronavirus Disease 2019 or Lung Cancer: What Should We Treat?

Authors:  Marco Russano; Fabrizio Citarella; Bruno Vincenzi; Giuseppe Tonini; Daniele Santini
Journal:  J Thorac Oncol       Date:  2020-04-10       Impact factor: 15.609

2.  CT imaging and clinical course of asymptomatic cases with COVID-19 pneumonia at admission in Wuhan, China.

Authors:  Heng Meng; Rui Xiong; Ruyuan He; Weichen Lin; Bo Hao; Lin Zhang; Zilong Lu; Xiaokang Shen; Tao Fan; Wenyang Jiang; Wenbin Yang; Tao Li; Jun Chen; Qing Geng
Journal:  J Infect       Date:  2020-04-12       Impact factor: 6.072

3.  Alert to Potential Contagiousness: A Case of Lung Cancer With Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Wen Ouyang; Jing Yu; Junhong Zhang; Conghua Xie
Journal:  J Thorac Oncol       Date:  2020-04-17       Impact factor: 15.609

4.  Pulmonary Pathology of Early-Phase 2019 Novel Coronavirus (COVID-19) Pneumonia in Two Patients With Lung Cancer.

Authors:  Sufang Tian; Weidong Hu; Li Niu; Huan Liu; Haibo Xu; Shu-Yuan Xiao
Journal:  J Thorac Oncol       Date:  2020-02-28       Impact factor: 15.609

  4 in total
  6 in total

1.  Cylindrical Tube Stethoscopes: The Value of Practical Equipment in the Management of Patients with Infectious Diseases.

Authors:  Jian Zhu; Chuan-Yang Jiang; Bin Huang; Ji-Min Hu; Si-Zhen Fang; Ke Huang; Yan-Hong Gao; Jiao Yu
Journal:  Infect Drug Resist       Date:  2022-07-07       Impact factor: 4.177

2.  Ground glass opacities of the lung before, during and post COVID-19 pandemic.

Authors:  Marcello Migliore
Journal:  Ann Transl Med       Date:  2021-07

3.  Cancer Metastases from Lung Adenocarcinoma Disappeared After Molecular Targeted Therapy: A Successfully Clinical Treatment Experience.

Authors:  Meng-Jie Li; Jun Wei; Guo-Ping Ai; Ying Liu; Jian Zhu
Journal:  Pharmgenomics Pers Med       Date:  2022-05-26

Review 4.  Lung Cancer and Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Identifying Important Knowledge Gaps for Investigation.

Authors:  Christian Rolfo; Noy Meshulami; Alessandro Russo; Florian Krammer; Adolfo García-Sastre; Philip C Mack; Jorge E Gomez; Nina Bhardwaj; Amin Benyounes; Rafael Sirera; Amy Moore; Nicholas Rohs; Claudia I Henschke; David Yankelevitz; Jennifer King; Yu Shyr; Paul A Bunn; John D Minna; Fred R Hirsch
Journal:  J Thorac Oncol       Date:  2021-11-10       Impact factor: 15.609

5.  Neglected Foreign Body Aspiration Mimicking Lung Cancer Recurrence.

Authors:  Lei Li; Meng-Jie Li; Liu Sun; Yuan-Liang Jiang; Jian Zhu
Journal:  Risk Manag Healthc Policy       Date:  2022-03-16

6.  Artificial Intelligence System Application in Miliary Lung Metastasis: Experience from a Rare Case.

Authors:  Yu Zhang; Yan Chen; Kun Li; Wen Jiang; Bi-Cheng Zhang
Journal:  Risk Manag Healthc Policy       Date:  2021-07-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.